Antibody generation service: platform choice and where the risk sits

Choosing the platform

1. Immunisation and hybridoma. The classical route gives affinity-matured antibodies against native epitopes and works well for immunogenic targets. It is slower, depends on an animal responding, and yields a hybridoma whose sequence you should insist on having so the reagent survives the freezer.
2. Phage and yeast display. Display screens very large libraries quickly and in vitro, so it handles toxic and non-immunogenic targets and gives fine control over selection conditions. Binders come out as sequences, which is convenient, but affinity maturation is a separate engineered step rather than a gift from the immune system.
3. Single B cell screening. Sequencing paired chains from individual B cells of an immunised animal combines native pairing with direct sequence output. It is the most expensive route and the one that most reliably gives renewable, sequenced leads from a real immune response.
4. Selection pressure is where you steer. Whatever the platform, what you find is what you selected for. Counter-selection against close homologues, selection at the pH or in the buffer the application uses, and screening in the assay format all change the leads. Specify these rather than leaving them to the provider's default.
5. Stage the contract at the first lead. Break the project at the point where leads exist and are characterised, before any engineering or production. That is the natural decision point, and a contract without it commits you to spending on a campaign that may have found nothing useful.

What you should own, and the rights in a phage display antibody library

Insist on the variable region sequences for every lead you pay to characterise. A sequence is reproducible anywhere and forever; a clone in a provider's freezer is a dependency and a single point of failure.

Clarify the position on background intellectual property in the platform itself, particularly for display libraries, since some carry downstream obligations that only become visible when the programme advances.

Characterising discovery antibodies before you commit

Ask for affinity measured by a stated method, specificity against a named counter-screen panel, cross-reactivity against the species you will work in, and behaviour in the intended assay format. A lead with only a binding signal on a plate is a candidate, not a result.

Developability screening matters if the antibody is ever going to be produced at scale: expression level, aggregation propensity and stability. Finding these problems after lead selection is a common and avoidable setback.

When a custom project is the cheaper route

If no catalogue reagent works, the choice is between continuing to buy and test and commissioning one. A custom project costs more up front and takes months, and it delivers a reagent characterised against your own material, which is precisely what an unvalidated catalogue has failed to provide.

Price it against what has already been spent. Laboratories routinely buy and discard several reagents, each with weeks of work attached, before considering a custom route, by which point the arithmetic has long favoured it. Put the acceptance criteria in the contract: which application, which species, which control has to pass.

Screening antibody libraries, and what a campaign delivers

Where a programme needs binders with defined properties rather than one detection reagent, the work moves from immunisation to screening a library against the target under the conditions that matter. That is a different service with a different deliverable, usually sequences rather than serum.

It is the right route when the binder has to be recombinant, reproducible indefinitely and characterised for affinity and epitope. It is the wrong route when a western blot reagent is all that is needed, where it costs far more than the problem is worth.

A zsgreen antibody and a stable tetrameric reporter

ZsGreen is unusually bright and stable and is tetrameric, so a zsgreen antibody may detect an incompletely denatured species running above the expected mass and a longer boil changes the band. Because the protein is bright, its own fluorescence is available as an independent check, and a blot disagreeing with the microscope usually means sample preparation rather than the antibody.

A foxo3 antibody and the name with an a

FOXO3 and FOXO3a are the same factor under two conventions, so a foxo3 antibody and a foxo3a antibody are the same target and searching one hides half the market. It is exported from the nucleus when phosphorylated by AKT, so location rather than level is the readout, and the family shares a domain which makes specificity data necessary.

An n antibody, and the ambiguity in one letter

A catalogue entry for an n antibody is ambiguous by itself: it may mean an antibody against a viral nucleocapsid protein, against the amino terminal region of a named protein, or a product whose name was truncated in a listing. The order has to name the antigen and the epitope region, because none of the three is substitutable for another.

A cdt1 antibody and a reagent worth preserving

A cdt1 antibody reports a replication licensing factor that is degraded through the cell cycle, so the signal changes with synchrony and a clone that works is worth keeping rather than re-deriving. Sequencing the variable regions of a proven clone is what turns a finite ascites stock into a permanent recombinant one.

Common questions

What is the difference between antibody generation and antibody production?

Generation is discovering binders against a target; production is making more of an antibody that already exists. Generation projects are discovery work with real failure risk, which is why they should be staged.

Which of the antibody discovery platforms should I choose?

Hybridoma for immunogenic targets where affinity matters and budget is limited; display for toxic, conserved or non-immunogenic targets and where selection control matters; single B cell where you want native pairing and sequenced leads and can afford it.

Can a generation campaign fail?

Yes, and it is the reason to stage the contract at the first characterised lead. Difficult targets, highly conserved epitopes and poor immunogens all produce campaigns with no usable binder.

Do I get the antibody sequence?

Only if the contract says so. Ask for the variable region sequences of every lead you pay to characterise, because that is what makes the reagent renewable independently of the provider.

When should I commission a custom antibody?

When no catalogue reagent has been validated for your target and application and you have already spent weeks testing candidates. Write the acceptance criteria into the contract: the application, the species and the control that has to pass.

Browse by service class

• Compare Gene synthesis on advertised prices